Development History and Feasibility Analysis of Mesenchymal Stem Cell Therapy for Type 2 Diabetes Mellitus
Year: 2026
Type: article
Abstract: Type 2 diabetes mellitus (T2DM) has become a major global public health burden, and existing drugs cannot reverse the progressive failure of pancreatic β-cell function. Mesenchymal stem cells (MSCs), by virtue of their immunomodulatory, anti-inflammatory, and tissue-repair properties, offer a new strategy for the causal treatment of T2DM. This article reviews the development history and mechanisms of action of MSC therapy for T2DM, including restoration of insulin-resistance signaling pathways, reversal of β-cell dedifferentiation, suppression of chronic low-grade inflammation, and exosome-mediated paracrine effects; summarizes evidence from preclinical animal studies and recent representative clinical studies, analyzing safety and efficacy; and discusses translational bottlenecks such as cellular heterogeneity, low homing efficiency, and the lack of standardization, together with countermeasures including genetic modification, patient stratification, and exosome engineering. Current evidence indicates that MSC therapy for T2DM is safe and feasible, with glucose-lowering and organ-protective potential; however, complete remission rates are low and therapeutic responses are highly heterogeneous, and routine clinical application still requires high-quality evidence-based support and standardized systems.
Source: Theoretical and Natural Science
Author: Haotian Yang
Institution: Southwest Jiaotong University
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Keywords: mesenchymal stem cells, type 2 diabetes, beta-cell dysfunction, insulin resistance, beta-cell dedifferentiation, low-grade inflammation, exosomes, paracrine signaling, stem cell homing, cellular heterogeneity, genetic modification of stem cells, patient stratification, exosome engineering, stem cell therapy safety and efficacy, translational barriers
Open Access status: hybrid
OpenAlex ID: W7235527454
